Cytokinetics Incorporated recently announced the presentation of additional data from the MAPLE-HCM clinical trial, which compared metoprolol and aficamten in patients with hypertrophic cardiomyopathy $(HCM)$ and left ventricular outflow tract obstruction. The new data were shared during three Late Breaking Science sessions at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and the American Heart Association Scientific Sessions 2025, and two presentations were simultaneously published in the Journal of the American College of Cardiology. The analyses included patient reported outcomes, cardiac biomarkers, and responder analyses. Results showed that treatment with aficamten led to greater reductions in cardiac biomarkers NT-proBNP and high sensitivity cardiac troponin I compared to metoprolol. Additionally, more patients receiving aficamten achieved significant improvements in patient-reported symptoms and clinical response categories. These findings build on earlier results demonstrating the superiority of aficamten over metoprolol in improving exercise capacity in this patient population.